EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Geron Corporation (GERN) fair value: what the stock is really worth

We calculate from audited financials what Geron Corporation is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN US3741631036

GC Geron Corporation logo Thin data Sep 13, 2026

Geron Corporation

GERN · US

Weakest SetupStrongly overvalued and low quality.

!Fair value $0.2700 · Strongly overvalued (−80%)
!Quality 32/100
!Mixed Growth (revenue 5y +273.5 %/yr)
!Loss-making · -33.1% net margin (TTM)
!Moderate debt · negative free cash flow
!Trails peers (2/10)
!Narrow moat 9/100
!Evidence only low, so the estimate is less certain
Watch Geron Corporation for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$5.09 $0.9900 Fair Value $0.2700 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.

How to read this chart

60‑month range $0.9900 – $5.09 · fair‑value band $0.1800 – $0.3400 · the $1.35 price screens above the $0.2700 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 13, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology.

Show more

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.

Stock analysis

Geron Corporation (GERN) currently trades at $1.35, while our model-based Fair Value estimate is $0.2700, implying the stock looks roughly 400.0% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: $0.1800 (bear) to $0.3400 (bull), the price of $1.35 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Geron Corporation reported revenue of $184M in FY2025 versus $1.4M in FY2021, a compound +239.0%/yr. Reported net income was −$85.8M in FY2025.

Key figures

Market cap $900M · P/S ratio 4.12 · EPS (TTM) $−0.1100 · Net margin −46.7% · Return on equity −27.1% · Return on assets (EBIT) −42.2% · Operating margin −0.5% · Revenue (TTM) $196M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).

What moves the price

The share trades about 33% below its 52-week high and 30% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −12% fair-value upside, at −80%, GERN screens richer than that median.

Fair Value models

Bear $0.1800 Fair Value $0.2700 Bull $0.3400
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $0.1800 $0.2400 $0.3500 54
All 1 models by family
Asset-Based
NCAV (Graham) $0.1800 $0.2400 $0.3500 54

Open the full fair value analysis →

Notify me when GERN reaches fair value

Put GERN on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 32/100

Of which business quality 34 · Market factors (momentum, volatility) 44

Profitability 14
Margins and returns on capital today
Quality Growth 88
Are margins and returns improving?
Cashflow 18
Earnings quality: real cash, not paper profit
Fin. Strength 41
Balance sheet, leverage, solvency risk
Investment 33
Disciplined investing over empire-building
Low Volatility 47
Calm price path (market factor)
Momentum 48
Price trend over the last 3–12 months (market factor)
52W Momentum 35
Distance to the 52-week high (market factor)
Net Issuance 24
Buybacks instead of dilution

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 36/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Latest YoY
+138.8%
Revenue growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+575.7%
Revenue growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+273.5%
Revenue growth/yr (29Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.0%
Share of sales kept as operating profit (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−30,400.4% (2020) → −29.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

GERN screens 400% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 627 stocks

Beats the industry median on 2/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 34 · Below median
Fair Value upside −83% · Bottom 25%
Profitability
Return on assets −4% · Above median
Net margin (TTM) −33% · Below median
Operating margin (TTM) −22% · Bottom 25%
Growth and dividend
Revenue growth 17% · Above median
Balance sheet
Debt / equity 0.53× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 4.18× · Priciest 25%
P/S (TTM) 4.61× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)86 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)74 · sector 97
DIVIDEND (yield)0 · sector 27

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $515.44 $566.98 +10%
Regeneron Pharmaceuticals, Inc REGN $781.49 $1,241 +59%
argenx SE ARGX €853.80 €752.12 −12%
BeOne Medicines AG 688235 ¥271.00 ¥47.36 −83%
Samsung Biologics Co 207940 1,415,000 KRW 1,556,500 KRW +10%
Alnylam Pharmaceuticals, Inc ALNY $248.68 $211.88 −15%
Royalty Pharma plc RPRX $58.61 $24.22 −59%
Celltrion, Inc 068270 178,200 KRW 74,519 KRW −58%
BioNTech SE BNTX $96.73 $63.31 −35%
Incyte Corporation INCY $121.47 $204.93 +69%

Compare Geron Corporation with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Geron Corporation · Fair Value
$0.2700 −400%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Geron Corporation Fair Value". https://www.fairvalue-calculator.com/stock/GERN

Frequently asked questions

Is Geron Corporation (GERN) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of $0.2700 versus a price of $1.35, about −80% upside (overvalued).
What is the fair value of GERN?
Our model-based fair value for Geron Corporation is $0.2700 (as of Sep 13, 2026), built from audited fundamentals. The current price: $1.35.
What is the quality score of GERN?
Geron Corporation has a Quality Score of 32/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Geron Corporation (GERN)?
Our model-based price target is the fair value of $0.2700 (as of Sep 13, 2026) from 1 valuation models. Cautious scenario $0.1800, optimistic scenario $0.3400. It is a calculation from audited fundamentals, not an analyst target.
What is the Geron Corporation stock forecast for 2026?
Our models put fair value at $0.2700, about −80% upside versus a price of $1.35 (overvalued). Cautious scenario $0.1800, optimistic scenario $0.3400. The calculation is refreshed regularly with new filings.
What is the revenue of Geron Corporation (GERN)?
Geron Corporation reported trailing-twelve-month revenue of about $196M (latest available figure, as of Sep 13, 2026).
What is the intrinsic value of Geron Corporation (GERN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Geron Corporation it is $0.2700 per share (as of Sep 13, 2026), against a price of $1.35. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Geron Corporation stock overvalued or undervalued in 2026?
As of Sep 13, 2026, GERN trades above its calculated fair value: price $1.35, fair value $0.2700, a gap of about −80% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of GERN?
No. The price is what the market pays today ($1.35); the fair value is what the company's own numbers justify ($0.2700). For Geron Corporation the two are $1.08 per share apart. That gap is exactly why we show both numbers side by side.
How much is Geron Corporation worth?
The market values Geron Corporation at about $900M (market capitalisation, as of Sep 13, 2026). Per share that is $1.35; our models calculate a fair value of $0.2700 per share.
What do the bullish and bearish scenarios say about GERN?
Our models span a range for Geron Corporation: cautious scenario $0.1800, base $0.2700, optimistic $0.3400 per share (as of Sep 13, 2026, price $1.35). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Geron Corporation (GERN)?
Balance-sheet figures for Geron Corporation (as of Sep 13, 2026): return on equity −28.3%, debt of 0.53 per unit of equity. They feed the Quality Score of 32/100, which measures business quality independently of the share price.
How far is GERN from its 52-week high?
Geron Corporation trades at $1.35, about 33% below its 52-week high of $2.01 and 30% above the low of $1.04 (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of $0.2700 is for.
Which stocks are comparable to Geron Corporation?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, BeOne Medicines AG, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Geron Corporation stock attractive at the current price?
The data as of Sep 13, 2026: price $1.35, calculated fair value $0.2700 (−80%), Quality Score 32/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of GERN calculated?
We run Geron Corporation through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.2700, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 32.0 % above its aggregate fair value. Geron Corporation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What should I pay attention to with Geron Corporation right now?
The price sits above even our optimistic bull case ($0.3400). The favourable scenario is already priced in. Weak quality (32/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.1800 to $0.3400) leaves room in how you read the outcome.

Key figures of Geron Corporation

How large is the market capitalisation of Geron Corporation (GERN)?
The market capitalisation of Geron Corporation is $900M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Geron Corporation (GERN)?
The price-to-sales ratio of Geron Corporation is 4.12 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Geron Corporation (GERN)?
Earnings per share at Geron Corporation are $−0.1100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Geron Corporation (GERN)?
The net margin of Geron Corporation is −46.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Geron Corporation (GERN)?
The return on equity (ROE) of Geron Corporation is −27.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Geron Corporation (GERN)?
On an EBIT basis the return on assets of Geron Corporation is −42.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Geron Corporation (GERN)?
The operating margin of Geron Corporation is −0.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Geron Corporation (GERN)?
Revenue at Geron Corporation is growing +30.9% versus a year earlier (3y avg +576%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Geron Corporation (GERN) generate?
The free cash flow of Geron Corporation is −$111M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Geron Corporation (GERN) carry?
The net debt of Geron Corporation is $172M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Geron Corporation in the live analysis

One click puts Geron Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.